Pharmaceutical News

RSS

Schering-Plough commits to chronic hepatitis C research

Schering-Plough has reaffirmed its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.

11 Apr 2007

U.S. District Court grants Mylan extension for consideration of Amlodipine Besylate exclusivity

Mylan Laboratories has announced that the U.S. District Court for the District of Columbia has extended the deadlines pertaining to Mylan's request for a temporary restraining order in its lawsuit seeking to stop the U.S. Food and Drug Administration (FDA) from approving any other Amlodipine Besylate abbreviated new drug applications (ANDAs).

11 Apr 2007

Transgenomic signs contract with OSI Pharmaceuticals for cancer genetic analysis

Transgenomic has announced that it has signed a contract with OSI Pharmaceuticals to complete an analysis of specific cancer pathway genes.

11 Apr 2007

Pharmatek Laboratories opens new facility in San Diego

Pharmatek Laboratories has announced the opening of its new 34,000 sq. ft. facility at 7330 Carroll Road, San Diego, California 92121.

11 Apr 2007

Pharmacopeia announces positive results in hypertension and diabetic nephropathy trial

Pharmacopeia ( NASDAQ:PCOP ) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.

11 Apr 2007

Renovis and Pfizer extend research collaboration

Renovis has announced an agreement with Pfizer to extend the term of the companies' worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1.

11 Apr 2007

Novalar Pharmaceuticals submits NDA for dental anesthetic reversal agent

Novalar Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for marketing approval of NV-101, a local dental anesthetic reversal agent.

11 Apr 2007

Most promising drugs in development for metabolic syndrome

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome.

11 Apr 2007

Canada plans to acquire MVA-based smallpox vaccine

The Department of National Defence (DND) in Canada has issued a request for proposal for the acquisition of MVA based smallpox vaccines for the protection of 10,000 people and an option for protecting another 10,000 people.

11 Apr 2007

Boehringer Ingelheim expands license agreement with GeneGo

GeneGo has announced that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers global locations and multiple departments.

11 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott and World Health Organization (WHO) Director-General, Margaret Chan, have agreed on a balanced approach to provide Kaletra/Aluvia (lopinavir/ritonavir) capsules and tablets to more patients in the developing world, while supporting continued long-term biopharmaceutical research and development.

10 Apr 2007

FASgen awarded grant for refinement of its serum fatty acid synthase

FASgen has announced that it has been awarded an SBIR grant from National Cancer Institute for refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS- Detect ELISA.

10 Apr 2007

Epilepsy drug retigabine safe and effective

A drug for epilepsy with a new mechanism of action is safe and effective, according to a study published in the April 10, 2007, issue of Neurology", the scientific journal of the American Academy of Neurology.

10 Apr 2007

China Medicine's ADTZ product highlighted at American Chemical Society's National Meeting

China Medicine Corporation has announced that the Company's proprietary ADTZ product was discussed as a viable means to reduce aflatoxins in the creation of ethanol based products from corn feed at the recent American Chemical Society, 233rd National Meeting Agricultural Biomass, Biobased Products, & Biofuels Symposium, which was held in Chicago, Illinois on March 25th through the 29th.

10 Apr 2007

Roche to acquire BioVeris

BioVeris Corporation has announced that the Company has reached a definitive agreement under which Roche will acquire BioVeris for $21.50 per share in cash, or a total of approximately $600 million.

From Roche Sequencing and Life Science 5 Apr 2007

Pharmacyclics undergoes 'file over protest' for Xcytrin NDA

Pharmacyclics, Inc. has announced its request to the U.S. Food and Drug Administration (FDA) that its New Drug Application (NDA) for Xcytrin (motexafin gadolinium) Injection be filed over protest.

5 Apr 2007

PhRMA statement on the Medicare prescription drug program

Pharmaceutical Research and Manufacturers of America Senior Vice President Ken Johnson issued the following statement on the AARP's campaign to modify the Medicare prescription drug program.

5 Apr 2007

Market study into the distribution of medicines in the UK

The OFT has launched a market study into the distribution of medicines in the UK. This decision follows recent and proposed distribution changes by leading UK medicine suppliers.

5 Apr 2007

Bayer Healthcare Pharmaceuticals launches in the U.S.

Bayer HealthCare Pharmaceuticals Inc. today announced its official U.S. launch. The new company incorporates the former Berlex Inc.into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

5 Apr 2007